The recent years have witnessed a significant increase in the demand for pork and gelatin, an increase in the prevalence of swine diseases, and growth in R&D expenditure for innovation of vaccines. According to the world meat consumption statistics provided by the US Department of Agriculture - Foreign Agricultural Service (USDA – FAS), 40.4% of the total meat consumption, across the globe, in 2017 is accounted for by pork alone. The report also states that per capita pork consumption (lb, carcass weight) has observed significant growth, across many regions, as shown in the graph.

This increase in pork consumption is expected to give rise to a growing need of keeping the swine population free from every possible disease that could affect swine and pose a threat to the human population, owing to the rise in prevalence of several zoonotic diseases. As a result of this, the requirement for a variety of swine vaccines, targeting various porcine diseases, is expected to grow.

Key Market Trends

Porcine Circovirus Associated Disease is Expected to Witness a Healthy Growth

PCV (Porcine Circovirus) is the smallest non-enveloped, single-stranded DNA virus, which replicates autonomously in eukaryotic cells, using the host polymerase for genome amplification. Generally, the price of vaccines targeting porcine circovirus associated disease (PCVAD) can range from USD 50 to around USD 500. Commercially available PCVAD vaccines can be of many types, mainly based upon the dosage, packaging size, age of the pig it is used on, and virus type. Some of the major brands manufacturing and selling porcine vaccines for PCVAD, globally, are Boehringer Ingelheim, Merck, and Zoetis, among others. The first FLEX Family swine vaccine for PCV2 protection in a single injection was Ingelvac CircoFLEX, by Boehringer Ingelheim. Hence, it is one of the revolutionary PCV2 vaccines in the market.

United States Holds a Significant Market Share

Increasing pork consumption, the growing prevalence of various swine diseases, and rising per capita animal healthcare expenditure are the factors due to which the United States is expected to retain its large market share.

Europe is the second-largest market for Porcine Vaccine is expected to follow North America, while Asia-Pacific is expected to demonstrate highest growth rate owing to factors such as increasing demand for animal-based food products, especially in South-East Asia, rise in awareness about porcine health, and recent advancements in the field of biotechnology. Hence, the aforementioned factors are expected to fuel the growth of the Porcine Vaccine Market in the Asia Pacific.

Competitive Landscape

The porcine vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence and are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion as well as farm animals.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support